No evidence for systemic low-grade inflammation in adult patients with early-treated phenylketonuria: The INGRAPH study.

C‐reactive‐protein cardiovascular risk cytokines inflammation phenylketonuria

Journal

JIMD reports
ISSN: 2192-8304
Titre abrégé: JIMD Rep
Pays: United States
ID NLM: 101568557

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 04 02 2023
revised: 16 04 2023
accepted: 26 04 2023
medline: 6 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

The question of an increased cardiovascular risk has been recently raised in adults with phenylketonuria (PKU). As low-grade systemic inflammation increases cardiovascular risk, the INGRAPH study aimed to evaluate low-grade inflammation in adult PKU patients compared to healthy controls and to determine the potential influence of Phe-controlled diet on inflammation. Twenty early-treated adult PKU patients, including a subgroup of 15 classical PKU patients, and 20 healthy volunteers were included. PKU patients and healthy subjects were matched on age, sex and body mass index class. Plasma concentrations of CRP, IFNg, IL1a, IL1b, IL2, IL6, IL10, and TNFα were measured in PKU patients and compared to controls. Plasma CRP was not different in the PKU group as compared to controls. No significant differences were observed between the two groups concerning plasma cytokines concentrations. Plasma CRP and cytokine profile were not different between "on diet" and "off diet" PKU patients. All these results were similar considering only the classical PKU subgroup. No differences were shown in plasma CRP and pro-inflammatory cytokines between adult PKU patients and healthy controls. Further studies are needed, including more patients and extensive characterization of systemic low-grade inflammation, as cardiovascular risk appears to be a new concern in adult PKU population.

Identifiants

pubmed: 37927482
doi: 10.1002/jmd2.12366
pii: JMD212366
pmc: PMC10623104
doi:

Types de publication

Journal Article

Langues

eng

Pagination

446-452

Informations de copyright

© 2023 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Eur J Pediatr. 2000 Oct;159 Suppl 2:S114-20
pubmed: 11043157
Mol Genet Metab. 2018 Nov;125(3):228-234
pubmed: 30266197
Int J Dev Neurosci. 2015 Dec;47(Pt B):259-65
pubmed: 26456498
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Lancet. 1997 Feb 15;349(9050):462-6
pubmed: 9040576
Circ Res. 2021 May 28;128(11):1728-1746
pubmed: 33998272
J Community Hosp Intern Med Perspect. 2018 Feb 06;8(1):21-22
pubmed: 29441161
Int J Neonatal Screen. 2020 Jul 29;6(3):
pubmed: 33239585
Orphanet J Rare Dis. 2019 Sep 6;14(1):213
pubmed: 31492166
Eur Heart J. 2020 Nov 7;41(42):4092-4099
pubmed: 32860034
J Inherit Metab Dis. 2011 Feb;34(1):165-71
pubmed: 21153445
Obes Surg. 2020 Oct;30(10):3852-3861
pubmed: 32358687
J Nutr Metab. 2017;2017:1909101
pubmed: 28546877
Ann Pharmacother. 2020 Oct;54(10):1021-1029
pubmed: 32425120
J Inherit Metab Dis. 2020 Sep;43(5):944-951
pubmed: 32392388
Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E885-95
pubmed: 22297302
Medicine (Baltimore). 2017 Dec;96(51):e9322
pubmed: 29390507
Mol Genet Metab. 2011 Aug;103(4):330-7
pubmed: 21601502
Cell Mol Life Sci. 2017 Aug;74(16):2899-2916
pubmed: 28314892
Am J Epidemiol. 2016 Feb 15;183(4):249-58
pubmed: 26823439
J Am Heart Assoc. 2021 Sep 7;10(17):e020351
pubmed: 34423658
Orphanet J Rare Dis. 2017 Oct 12;12(1):162
pubmed: 29025426
N Engl J Med. 2000 Mar 23;342(12):836-43
pubmed: 10733371
Cytokine. 2015 Feb;71(2):188-98
pubmed: 25461398
Acta Sci Pol Technol Aliment. 2016 Apr-Jun;15(2):221-225
pubmed: 28071012
Sci Rep. 2016 May 31;6:26996
pubmed: 27243383
Mol Genet Metab Rep. 2018 Sep 28;17:43-44
pubmed: 30294544

Auteurs

Chloé Giret (C)

Service de médecine interne CHRU de Tours Tours France.
Université de Tours Tours France.

Yann Dos Santos (Y)

Université de Tours Tours France.
UMR INSERM, "iBrain" 1253 Tours France.

Hélène Blasco (H)

Université de Tours Tours France.
UMR INSERM, "iBrain" 1253 Tours France.
Laboratoire de biochimie, CHRU de Tours Tours France.
Centre de référence des maladies héréditaires du métabolisme Tours France.

Christophe Paget (C)

Université de Tours Tours France.
Centre d'étude des Pathologies Respiratoires (CEPR) UMR INSERM 1100 Tours France.

Loïc Gonzalez (L)

Université de Tours Tours France.
Centre d'étude des Pathologies Respiratoires (CEPR) UMR INSERM 1100 Tours France.

Nathalie Tressel (N)

Service de médecine interne CHRU de Tours Tours France.
Centre de référence des maladies héréditaires du métabolisme Tours France.

Maeva Dieu (M)

Service de médecine interne CHRU de Tours Tours France.

Adrien Bigot (A)

Service de médecine interne CHRU de Tours Tours France.
Centre de référence des maladies héréditaires du métabolisme Tours France.

Valérie Gissot (V)

Centre d'investigation clinique, CHRU de Tours Tours France.

Alexandra Audemard-Verger (A)

Service de médecine interne CHRU de Tours Tours France.
Université de Tours Tours France.
Centre d'étude des Pathologies Respiratoires (CEPR) UMR INSERM 1100 Tours France.

François Maillot (F)

Service de médecine interne CHRU de Tours Tours France.
Université de Tours Tours France.
UMR INSERM, "iBrain" 1253 Tours France.
Centre de référence des maladies héréditaires du métabolisme Tours France.

Classifications MeSH